Backs FY26 gross margin view 77%-79%. “Importantly, we are now entering a data-rich period, with key readouts this year expected from Part A of our Phase 2 study of PCRX-201 in knee osteoarthritis, as well as our registrational studies for ZILRETTA in shoulder osteoarthritis and iovera degrees in spasticity. As we move through 2026, we will continue to execute our 5×30 strategy to drive durable revenue growth, deliver clinical innovation, and create long-term value for patients and shareholders into and beyond 2030,” continued Lee.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PCRX:
- PCRX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Exparel’s Proven Clinical and Economic Value Underpins Buy Rating and $38 Price Target on Pacira BioSciences
- Pacira real-world data clearer in hip arthroplasty, says H.C. Wainwright
- Pacira presents data showing lower healthcare costs for Exparel
- Pacira price target lowered to $25 from $27 at Barclays